Short answer
A RET variant of uncertain significance, or VUS, means the lab found a RET change but does not have enough evidence to call it disease-causing or benign. That is different from a pathogenic RET variant used to diagnose hereditary MEN2 risk. A VUS should be interpreted with the clinical picture, family history, the report wording, and genetics follow-up. It usually should not be used alone for irreversible medical or family decisions.
What a RET VUS means
| Result wording | What it tells you | Why it matters |
|---|---|---|
| Pathogenic or likely pathogenic RET variant | Evidence supports a hereditary MEN2 diagnosis or risk state. | Thyroid, adrenal, and family screening decisions may change. |
| RET VUS | Evidence is incomplete or conflicting. | It cannot confirm or rule out MEN2. |
| RET finding from tumor-only testing | The change may be somatic rather than inherited. | Germline testing may still be needed if family risk is a concern. |
What it does not mean
MedlinePlus Genetics and GeneReviews both emphasize the same boundary: a VUS is an uninformative result. It does not prove that someone has MEN2, and it does not prove that the variant is harmless. The result also does not predict how severe disease would be, and it should not be used as a stand-alone reason for major surgery or for cascade testing unless a genetics team has a specific reason to do so.
Another common trap is confusing a tumor finding with an inherited one. A RET change reported on tumor testing may simply reflect the tumor biology. In that case, separate germline testing and clinical review are what usually clarify whether there is true familial risk.
How follow-up usually works
- Confirm the exact variant, transcript, and classification on the report.
- Review personal and family history for medullary thyroid cancer, pheochromocytoma, hyperparathyroidism, or MEN2 features.
- Ask whether the result came from germline blood or saliva testing, tumor-only testing, or direct-to-consumer raw data.
- Ask who will track reclassification and how updates will be communicated.
- Use the rest of the clinical picture to decide whether endocrine surveillance or extra testing is actually needed.
When family history changes the next step
Follow-up matters more when a RET VUS sits in a strong MEN2 family history, when the lab may reclassify the variant later, or when targeted family testing could help clarify what is inherited. Genetics counseling helps decide whether to wait, retest, or treat the finding as uncertain.
When specialist review matters
Specialist review matters when a RET VUS is being treated like a final answer, because genetics can later reclassify the variant and family history may change how the result is used.
How genetic testing is done
Genetic testing is usually done with blood or saliva, and the lab workflow depends on whether the question is a targeted variant, a panel, or confirmation after a clinical finding. Genetics counseling can help clarify whether the next step is a new test, family testing, or a different clinical workup.
Questions to ask
- What exact RET variant, transcript, and classification were reported?
- Was this germline testing, tumor testing, or another sample type?
- Are there MEN2 features in me or my family that make this more important?
- Should the lab or clinician notify me if the variant is reclassified?
FAQ
What does a RET VUS mean?
A RET variant of uncertain significance means the lab found a RET change but does not have enough evidence to call it disease-causing or benign.
Does a RET VUS diagnose MEN2?
No. A VUS does not establish or rule out MEN2 by itself, and it should not be treated like a confirmed pathogenic RET result.
Should relatives be tested for a RET VUS?
Usually not for medical decision-making alone. Family testing may be considered by genetics specialists in selected situations, but a VUS is not the same as a known familial pathogenic variant.
Can a RET VUS be reclassified later?
Yes. New evidence can move a VUS toward benign or pathogenic, so patients should ask who will notify them if the classification changes.
What if tumor testing found RET but blood testing is negative?
That pattern can mean a somatic tumor change rather than inherited risk. Tumor-only findings usually need separate germline interpretation.
When should I talk with genetics or endocrinology?
Talk with specialists when the result affects thyroid, adrenal, or family-risk decisions, or when the report wording is unclear.
Related guides: RET tumor testing vs germline testing, negative RET testing with medullary thyroid cancer, RET VUS family testing questions, and medullary thyroid cancer RET result routing.